CAS · 202409-33-4
Product Overview
Etoricoxib丨202409-33-4 is a selective COX-2 inhibitor belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is widely used for its analgesic, anti-inflammatory, and antipyretic properties, particularly in the treatment of arthritis and musculoskeletal disorders.
Product Specifications
| Property | Specification |
|---|---|
| Appearance | White to light yellow crystalline powder |
| Heavy Metal | 10 ppm max |
| Any Single Impurity | ≤ 1.0% |
| Total Impurities | ≤ 2.0% |
| Purity | 98% min |
Applications
Detailed application notes for this product are available on request. Contact our technical team for the full application dossier, formulation guidance and regulatory documentation.
Benefits
✅ Selective COX-2 Inhibition
Targets COX-2 enzyme selectively, reducing pain and inflammation while minimizing gastric irritation and ulcer risks compared to traditional NSAIDs.
✅ Effective for Chronic Pain Management
Provides long-lasting relief for patients with chronic inflammatory conditions such as arthritis and gout.
✅ Lower Gastrointestinal Side Effects
Causes fewer gastric ulcers, bleeding, and stomach irritation compared to non-selective NSAIDs.
✅ Once-Daily Dosing for Convenience
Long half-life allows for once-daily administration, improving patient compliance.
Conclusion
Etoricoxib丨202409-33-4 is a highly effective COX-2 inhibitor used for pain relief and inflammation management, especially in arthritis, gout, and acute pain conditions. Its gastrointestinal safety profile and once-daily dosing make it a preferred choice for long-term use in many patients.
Previous
Vancomycin Hydrochloride丨CAS 1404-93-9
Next